In recent years, there has been an increasing focus on investigating the role of Tau in the onset and progression of Alzheimer’s Disease (AD), and in other neurodegenerative diseases associated with the accumulation of pathological misfolded Tau, such as progressive supranuclear palsy (PSP) and frontotemporal lobar degeneration (FTLD). Studies using recently introduced second-generation Tau tracers suggests that these tracers are binding to Tau with higher specificity compared to previous tracers, leading to increased interest in Tau within clinical studies. However, it’s still unclear what role Tau imaging will play in clinical trials: should Tau be used as a clinical endpoint; and how does it link to other biomarkers such as amyloid-beta, with some studies suggesting that amyloid-beta triggers the spread of Tau beyond the MTL region.
Given that the majority of Tau studies have been conducted using first-generation PET tracers, which had shown high incidences of off-site binding, it will be important to review the current data to understand what we know about Tau in AD and how second-generation tracers are being applied in clinical studies. Additionally, this webinar will cover the steps being taken to advance Tau PET operational and analytical methodologies in AD clinical studies and other Tau-related neurodegenerative diseases.
- Victor L. Villemagne, Associate Professor, Department of Medicine, Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, The Florey Institute of Neuroscience and Mental Health, The University of Melbourne
- Richard Manber, Biomarker Scientist, IXICO
The spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive ataxia disorders. SCA Global is a worldwide initiative for clinical research in SCAs and provides a flexible and open research platform to pursue the following goals: 1. To better understand the manifestation, evolution and impact of the various SCAs, 2. To develop and validate biomarkers which can be used in future interventional trials, 3. To facilitate access to people with SCAs who are willing to participate in clinical trials.
The AAT-AD/PD™ Focus Meeting 2020 will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
A central theme will be to further advance innovative strategies in therapy and prevention, clinical trials and diagnostic markers discussed in the sessions and corridors at AD/PD™ 2019, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing for a better future for patients and families affected by neurodegenerative diseases.